Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of Directors
01 sept. 2020 16h02 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a biotechnology company developing new treatments for...
Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
10 août 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments...
Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC
27 juil. 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
Guidance being incorporated into global study protocolEnrollment of first patient now expected in August CHARLOTTESVILLE, Va., July 27, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc....
Diffusion Pharmaceuticals Files IND for International Phase 1b/2b COVID-19 Clinical Program With TSC
07 juil. 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
Phase 1b dosing expected to begin this month Data read-out expected later this quarter CHARLOTTESVILLE, Va., July 07, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)...
Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of TSC in COVID-19 Patients
11 juin 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., June 11, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “Company”) announces the submission of a Clinical Trial Application (CTA) to the...
Diffusion Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
01 juin 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., June 01, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”) announces that on May 29, 2020 it received written notice from...
Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program
26 mai 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
First U.S. study to feature double-blinded, controlled, randomized trial design with safety and oxygenation endpointsFDA recommends incorporating remdesivir, where available CHARLOTTESVILLE, Va.,...
Diffusion Pharmaceuticals Inc. Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market
20 mai 2020 13h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 20, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments...
Diffusion Pharmaceuticals Expands Clinical Trial Program of TSC for the Treatment of COVID-19 Patients to Include the Romanian National Institute of Infectious Diseases
20 mai 2020 08h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 20, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments...
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
18 mai 2020 09h05 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 18, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments...